What is Wrig Nanosystems?
Wrig Nanosystems operates at the intersection of biotechnology and consumer electronics, primarily through its TrueHb Nord platform. The company specializes in US-patented healthcare technology designed to democratize blood analysis. Its flagship TrueHb Nord Hemoglobin Meter provides lab-accurate results in under 30 seconds, catering to patients managing chronic conditions such as anemia, chronic kidney disease, and oncology-related health challenges. By integrating Bluetooth connectivity and intuitive user interfaces, Wrig Nanosystems is effectively shifting the paradigm of personal health management from reactive clinical visits to proactive, home-based monitoring. This approach not only improves patient outcomes but also reduces the operational burden on healthcare systems by facilitating remote diagnostic capabilities.
How much funding has Wrig Nanosystems raised?
Wrig Nanosystems has raised a total of $2.3M across 1 funding round:
Unspecified
$2.3M
Unspecified (2015): $2.3M, investors not publicly disclosed
Key Investors in Wrig Nanosystems
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Wrig Nanosystems?
With this major enterprise-level funding, Wrig Nanosystems is poised to scale its manufacturing capabilities and expand its footprint in the global digital health market. The strategic roadmap likely involves deepening its integration with telehealth ecosystems and enhancing its data analytics suite to provide longitudinal health insights for chronic disease management. As the company matures, the focus will shift toward regulatory expansion in international markets and the potential development of a broader diagnostic portfolio, leveraging its existing core competency in rapid, point-of-care hemoglobin measurement. The firm remains a critical player to watch as the industry continues to prioritize decentralized care models.
See full Wrig Nanosystems company page
